Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-

[Guest guest]

Antivir Ther. 2006;11(5):567-74.

Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and

HIV-positive individuals: results from an inter-cohort analysis.

Puoti M, Cozzi-Lepri A, Arici C, Moller NF, Lundgren JD, Ledergerber B,

Rickenbach M, Suarez-Lozano I, Garrido M, Dabis F, Winnock M, Milazzo L,

Gervais A, Raffi F, Gill J, Rockstroh J, Ourishi N, Mussini C, Castagna A,

De Luca A, Monforte A; HBV-HIV International Intercohort Study Group.

Clinica di Malattie Infettive e Tropical, Universita degli Studi di Brescia,

Brescia, Italy. m.puoti@...

BACKGROUND: The impact of lamivudine (3TC) as part of combination

antiretroviral therapy (cART) on the risk of liver-related death (LRD) in

HIV/hepatitis B virus (HBV)-coinfected patients has not been extensively

studied. METHODS: We performed an analysis involving HIV/HBV-coinfected

patients in 13 cohorts who initiated cART. The end-point was LRD--that is,

death with concomitant decompensated liver disease (DLD) or hepatocellular

carcinoma--as the main cause. Incidence rates of LRD after initiation of

cART were expressed as number of events per 100 person-years of follow-up

(PYFU). A Poisson regression model adjusted for cohort, gender, mode of HIV

transmission, CD4+ T-cell count at cART initiation, liver disease pre-cART,

duration of 3TC before cART, and hepatitis C virus was used to assess the

association between use of 3TC and risk of LRD. Results: We analysed 2,041

patients. Follow-up after starting cART was 7,648 PYFU (5,569 spent on

3TC-containing regimens) with a median per person of 48 months (range:

2-91). Of the total, 217 subjects died; 57 deaths were liver-related

resulting in a rate of 7.5 per 1,000 PYFU [95% confidence intervals (CI):

5.6-9.7]. The relative risk of LRD per extra year of 3TC use was 0.73 (95%

CI: 0.59-0.90, P = 0.004). CONCLUSION: The use of 3TC was associated with a

reduced risk of LRD over 4 years of follow-up. This study supports the

current view that the use of 3TC as part of cART should be considered in

patients who are tested positive for HBsAg.

PMID: 16964824 [PubMed - in process]

_________________________________________________________________

Share your special moments by uploading 500 photos per month to Windows Live

Spaces

http://clk.atdmt.com/MSN/go/msnnkwsp0070000001msn/direct/01/?href=http://www.get\

..live.com/spaces/features

[Guest guest]

Antivir Ther. 2006;11(5):567-74.

Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and

HIV-positive individuals: results from an inter-cohort analysis.

Puoti M, Cozzi-Lepri A, Arici C, Moller NF, Lundgren JD, Ledergerber B,

Rickenbach M, Suarez-Lozano I, Garrido M, Dabis F, Winnock M, Milazzo L,

Gervais A, Raffi F, Gill J, Rockstroh J, Ourishi N, Mussini C, Castagna A,

De Luca A, Monforte A; HBV-HIV International Intercohort Study Group.

Clinica di Malattie Infettive e Tropical, Universita degli Studi di Brescia,

Brescia, Italy. m.puoti@...

BACKGROUND: The impact of lamivudine (3TC) as part of combination

antiretroviral therapy (cART) on the risk of liver-related death (LRD) in

HIV/hepatitis B virus (HBV)-coinfected patients has not been extensively

studied. METHODS: We performed an analysis involving HIV/HBV-coinfected

patients in 13 cohorts who initiated cART. The end-point was LRD--that is,

death with concomitant decompensated liver disease (DLD) or hepatocellular

carcinoma--as the main cause. Incidence rates of LRD after initiation of

cART were expressed as number of events per 100 person-years of follow-up

(PYFU). A Poisson regression model adjusted for cohort, gender, mode of HIV

transmission, CD4+ T-cell count at cART initiation, liver disease pre-cART,

duration of 3TC before cART, and hepatitis C virus was used to assess the

association between use of 3TC and risk of LRD. Results: We analysed 2,041

patients. Follow-up after starting cART was 7,648 PYFU (5,569 spent on

3TC-containing regimens) with a median per person of 48 months (range:

2-91). Of the total, 217 subjects died; 57 deaths were liver-related

resulting in a rate of 7.5 per 1,000 PYFU [95% confidence intervals (CI):

5.6-9.7]. The relative risk of LRD per extra year of 3TC use was 0.73 (95%

CI: 0.59-0.90, P = 0.004). CONCLUSION: The use of 3TC was associated with a

reduced risk of LRD over 4 years of follow-up. This study supports the

current view that the use of 3TC as part of cART should be considered in

patients who are tested positive for HBsAg.

PMID: 16964824 [PubMed - in process]

_________________________________________________________________

Share your special moments by uploading 500 photos per month to Windows Live

Spaces

http://clk.atdmt.com/MSN/go/msnnkwsp0070000001msn/direct/01/?href=http://www.get\

..live.com/spaces/features

[Guest guest]

Antivir Ther. 2006;11(5):567-74.

Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and

HIV-positive individuals: results from an inter-cohort analysis.

Puoti M, Cozzi-Lepri A, Arici C, Moller NF, Lundgren JD, Ledergerber B,

Rickenbach M, Suarez-Lozano I, Garrido M, Dabis F, Winnock M, Milazzo L,

Gervais A, Raffi F, Gill J, Rockstroh J, Ourishi N, Mussini C, Castagna A,

De Luca A, Monforte A; HBV-HIV International Intercohort Study Group.

Clinica di Malattie Infettive e Tropical, Universita degli Studi di Brescia,

Brescia, Italy. m.puoti@...

BACKGROUND: The impact of lamivudine (3TC) as part of combination

antiretroviral therapy (cART) on the risk of liver-related death (LRD) in

HIV/hepatitis B virus (HBV)-coinfected patients has not been extensively

studied. METHODS: We performed an analysis involving HIV/HBV-coinfected

patients in 13 cohorts who initiated cART. The end-point was LRD--that is,

death with concomitant decompensated liver disease (DLD) or hepatocellular

carcinoma--as the main cause. Incidence rates of LRD after initiation of

cART were expressed as number of events per 100 person-years of follow-up

(PYFU). A Poisson regression model adjusted for cohort, gender, mode of HIV

transmission, CD4+ T-cell count at cART initiation, liver disease pre-cART,

duration of 3TC before cART, and hepatitis C virus was used to assess the

association between use of 3TC and risk of LRD. Results: We analysed 2,041

patients. Follow-up after starting cART was 7,648 PYFU (5,569 spent on

3TC-containing regimens) with a median per person of 48 months (range:

2-91). Of the total, 217 subjects died; 57 deaths were liver-related

resulting in a rate of 7.5 per 1,000 PYFU [95% confidence intervals (CI):

5.6-9.7]. The relative risk of LRD per extra year of 3TC use was 0.73 (95%

CI: 0.59-0.90, P = 0.004). CONCLUSION: The use of 3TC was associated with a

reduced risk of LRD over 4 years of follow-up. This study supports the

current view that the use of 3TC as part of cART should be considered in

patients who are tested positive for HBsAg.

PMID: 16964824 [PubMed - in process]

_________________________________________________________________

Share your special moments by uploading 500 photos per month to Windows Live

Spaces

http://clk.atdmt.com/MSN/go/msnnkwsp0070000001msn/direct/01/?href=http://www.get\

..live.com/spaces/features

[Guest guest]

Antivir Ther. 2006;11(5):567-74.

Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and

HIV-positive individuals: results from an inter-cohort analysis.

Puoti M, Cozzi-Lepri A, Arici C, Moller NF, Lundgren JD, Ledergerber B,

Rickenbach M, Suarez-Lozano I, Garrido M, Dabis F, Winnock M, Milazzo L,

Gervais A, Raffi F, Gill J, Rockstroh J, Ourishi N, Mussini C, Castagna A,

De Luca A, Monforte A; HBV-HIV International Intercohort Study Group.

Clinica di Malattie Infettive e Tropical, Universita degli Studi di Brescia,

Brescia, Italy. m.puoti@...

BACKGROUND: The impact of lamivudine (3TC) as part of combination

antiretroviral therapy (cART) on the risk of liver-related death (LRD) in

HIV/hepatitis B virus (HBV)-coinfected patients has not been extensively

studied. METHODS: We performed an analysis involving HIV/HBV-coinfected

patients in 13 cohorts who initiated cART. The end-point was LRD--that is,

death with concomitant decompensated liver disease (DLD) or hepatocellular

carcinoma--as the main cause. Incidence rates of LRD after initiation of

cART were expressed as number of events per 100 person-years of follow-up

(PYFU). A Poisson regression model adjusted for cohort, gender, mode of HIV

transmission, CD4+ T-cell count at cART initiation, liver disease pre-cART,

duration of 3TC before cART, and hepatitis C virus was used to assess the

association between use of 3TC and risk of LRD. Results: We analysed 2,041

patients. Follow-up after starting cART was 7,648 PYFU (5,569 spent on

3TC-containing regimens) with a median per person of 48 months (range:

2-91). Of the total, 217 subjects died; 57 deaths were liver-related

resulting in a rate of 7.5 per 1,000 PYFU [95% confidence intervals (CI):

5.6-9.7]. The relative risk of LRD per extra year of 3TC use was 0.73 (95%

CI: 0.59-0.90, P = 0.004). CONCLUSION: The use of 3TC was associated with a

reduced risk of LRD over 4 years of follow-up. This study supports the

current view that the use of 3TC as part of cART should be considered in

patients who are tested positive for HBsAg.

PMID: 16964824 [PubMed - in process]

_________________________________________________________________

Share your special moments by uploading 500 photos per month to Windows Live

Spaces

http://clk.atdmt.com/MSN/go/msnnkwsp0070000001msn/direct/01/?href=http://www.get\

..live.com/spaces/features